Overview

Latanoprost Versus Fotil

Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
0
Participant gender:
All
Summary
To compare the intraocular pressure effect and safety of latanoprost 0.005% given every evening versus PTFC given twice daily.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pharmaceutical Research Network
Treatments:
Latanoprost
Criteria
Inclusion Criteria:

- adults with primary open-angle or pigment dispersion glaucoma, or ocular hypertension

- untreated intraocular pressure should be between 24-36 mm Hg inclusive

- visual acuity should be 5/50 or better in both eyes

Exclusion Criteria:

- presence of exfoliation syndrome or exfoliation glaucoma

- contraindications to study medications

- any anticipated change in systemic hypotensive therapy